Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMIX NASDAQ:QNRX NASDAQ:SINT NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$0.41+1.0%$0.38$0.20▼$2.64$2.83M-1.431.94 million shs102,235 shsQNRXQuoin Pharmaceuticals$4.49+4.7%$5.79$4.11▼$41.80$9.02M1.5630,541 shs20,178 shsSINTSintx Technologies$2.03-9.4%$2.42$1.86▼$6.78$8.77M0.6665,521 shs116,533 shsVVOSVivos Therapeutics$0.86+24.8%$0.90$0.55▼$7.95$12.01M6.1133,333 shs67.97 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical+0.99%+2.50%+6.52%-4.36%-75.00%QNRXQuoin Pharmaceuticals+4.66%-11.26%-30.17%-48.21%-50.11%SINTSintx Technologies-9.38%-9.38%-15.42%-25.37%-27.76%VVOSVivos Therapeutics+24.84%+23.50%+20.09%-35.00%-63.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$0.41+1.0%$0.38$0.20▼$2.64$2.83M-1.431.94 million shs102,235 shsQNRXQuoin Pharmaceuticals$4.49+4.7%$5.79$4.11▼$41.80$9.02M1.5630,541 shs20,178 shsSINTSintx Technologies$2.03-9.4%$2.42$1.86▼$6.78$8.77M0.6665,521 shs116,533 shsVVOSVivos Therapeutics$0.86+24.8%$0.90$0.55▼$7.95$12.01M6.1133,333 shs67.97 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical+0.99%+2.50%+6.52%-4.36%-75.00%QNRXQuoin Pharmaceuticals+4.66%-11.26%-30.17%-48.21%-50.11%SINTSintx Technologies-9.38%-9.38%-15.42%-25.37%-27.76%VVOSVivos Therapeutics+24.84%+23.50%+20.09%-35.00%-63.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMIXAutonomix Medical 2.00Hold$2.00387.80% UpsideQNRXQuoin Pharmaceuticals 1.00SellN/AN/ASINTSintx Technologies 2.50Moderate Buy$9.33359.77% UpsideVVOSVivos Therapeutics 2.25Hold$2.80223.89% UpsideCurrent Analyst Ratings BreakdownLatest AMIX, SINT, VVOS, and QNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SINTSintx Technologies Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/4/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $3.106/3/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/2/2026AMIXAutonomix Medical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/20/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/18/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/4/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/22/2026QNRXQuoin Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/22/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.004/21/2026SINTSintx Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMIXAutonomix MedicalN/AN/AN/AN/A$0.85 per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$15.64 per shareN/ASINTSintx Technologies$1.02M8.60N/AN/A$0.80 per share2.54VVOSVivos Therapeutics$17.44M0.69N/AN/A($0.16) per share-5.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMIXAutonomix Medical-$16.72M-$3.55N/AN/AN/AN/A-239.36%-192.46%8/12/2026 (Estimated)QNRXQuoin Pharmaceuticals-$15.81M-$29.56N/AN/AN/AN/A-489.85%-221.29%8/6/2026 (Estimated)SINTSintx Technologies-$10.36M-$5.07N/AN/AN/A-1,058.60%-366.49%-115.04%8/13/2026 (Estimated)VVOSVivos Therapeutics-$21.17M-$2.14N/AN/AN/A-127.70%-2,325.64%-98.12%8/18/2026 (Estimated)Latest AMIX, SINT, VVOS, and QNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026VVOSVivos Therapeutics-$0.45-$0.52-$0.07-$0.52$4.35 million$5.14 million5/15/2026Q1 2026SINTSintx Technologies-$0.66-$0.70-$0.04-$0.70$0.30 million$0.38 million5/7/2026Q1 2026QNRXQuoin Pharmaceuticals-$2.17-$1.77+$0.40-$1.77N/AN/A4/15/2026Q4 2025VVOSVivos Therapeutics-$0.4950-$0.58-$0.0850-$0.58$7.10 million$3.82 million3/27/2026Q4 2025QNRXQuoin Pharmaceuticals-$6.42-$14.80-$8.38-$1.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMIXAutonomix MedicalN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMIXAutonomix MedicalN/A4.454.45QNRXQuoin PharmaceuticalsN/A2.872.87SINTSintx TechnologiesN/A1.040.70VVOSVivos Therapeutics3.310.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMIXAutonomix Medical10.78%QNRXQuoin Pharmaceuticals8.63%SINTSintx Technologies18.38%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipAMIXAutonomix Medical6.20%QNRXQuoin Pharmaceuticals13.46%SINTSintx Technologies4.08%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMIXAutonomix Medical16.91 million6.48 millionN/AQNRXQuoin Pharmaceuticals42.01 million1.74 millionNot OptionableSINTSintx Technologies404.32 million4.14 millionNot OptionableVVOSVivos Therapeutics16013.90 million13.60 millionOptionableAMIX, SINT, VVOS, and QNRX HeadlinesRecent News About These CompaniesVivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial PositionJune 5 at 8:51 AM | quiverquant.comQVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingJune 5 at 8:45 AM | globenewswire.comVivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic ShiftsMay 29, 2026 | finance.yahoo.comVivos Therapeutics Balances Rapid Growth With Cash StrainMay 22, 2026 | tipranks.comVivos Therapeutics Earnings Call: Growth Meets Cash StrainMay 21, 2026 | tipranks.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 21, 2026 | finanznachrichten.deVivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call TranscriptMay 21, 2026 | seekingalpha.comVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 20, 2026 | globenewswire.comVivos Therapeutics Delays Quarterly FilingMay 15, 2026 | tipranks.comAnalysts see 200%+ upside in these 3 high-risk stocks: here's why?May 9, 2026 | invezz.comIVivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47April 29, 2026 | msn.comVivos Therapeutics Faces Nasdaq Listing Compliance ChallengesApril 22, 2026 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call TranscriptApril 17, 2026 | insidermonkey.comVivos Therapeutics Q4 Earnings Call HighlightsApril 17, 2026 | defenseworld.netDVivos Therapeutics Balances Growth Hopes With Cash StrainApril 16, 2026 | tipranks.comVivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potentialApril 16, 2026 | seekingalpha.comVivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ...April 16, 2026 | finance.yahoo.comVivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call TranscriptApril 15, 2026 | seekingalpha.comVivos Therapeutics Reports Full Year 2025 Financial ResultsApril 15, 2026 | globenewswire.comVivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026April 15, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMIX, SINT, VVOS, and QNRX Company DescriptionsAutonomix Medical NASDAQ:AMIX$0.41 +0.00 (+0.99%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.40 -0.01 (-3.41%) As of 06/5/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Quoin Pharmaceuticals NASDAQ:QNRX$4.49 +0.20 (+4.66%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.46 -0.03 (-0.56%) As of 06/5/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sintx Technologies NASDAQ:SINT$2.03 -0.21 (-9.38%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.02 -0.01 (-0.49%) As of 06/5/2026 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.Vivos Therapeutics NASDAQ:VVOS$0.86 +0.17 (+24.84%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.82 -0.05 (-5.73%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
